Publication:
Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience

Placeholder

Organizational Units

Program

School / College / Institute

KUH (KOÇ UNIVERSITY HOSPITAL)

KU-Authors

KU Authors

Co-Authors

Akdag, Goncagul
Dogan, Akif
Yuksel, Zeynep
Yildirim, Sedat
Kinikoglu, Oguzcan
Kudu, Emre
Surmeli, Heves
Odabas, Hatice
Yildirim, Mahmut Emre
Turan, Nedim

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Introduction Testicular germ cell tumors (seminoma/non-seminoma) are the most common carcinomas in young males, comprising approximately 1% of all carcinomas. In stage-I disease, orchiectomy can cure approximately 85% of patients. Post-surgical options are adjuvant therapy and active surveillance. Our study examined the effects of management options on stage-I seminoma patients followed in our center.Methods We evaluated the patients with stage-I testicular seminoma who underwent radical orchiectomy and followed up in the oncology center between 2001 and 2022. The outcomes of management options, survivals were retrospectively analyzed. The prognostic significance of risk factors for relapse on survival was evaluated.ResultsOf the 140 patients with stage-I seminoma, 49 (35%) were treated with adjuvant therapy, and 91 (65%) underwent surveillance. The median follow-up duration was 37 months. During the follow-up period, nine patients in the active surveillance group and four in the adjuvant therapy group had a recurrence. There was no statistically significant difference between the two groups (p = 0.67). In the surveillance group, the univariate and multivariate analyzes identified the presence of lymphovascular invasion (p = 0.005, HR: 0.13) as significant prognostic factor for disease-free survival (DFS). In the surveillance cohort, the 5-year DFS rate was 60% for patients with lymphovascular invasion and 93% for those without. There was statistical significance between the two groups (p = 0.003).Conclusion Our study shows that adjuvant therapy does not significantly improve DFS compared to surveillance in patients. In addition, it has been shown that lymphovascular invasion is an important prognostic indicator for DFS in determining the treatment strategy.

Source

Publisher

Springer

Subject

Urology and nephrology

Citation

Has Part

Source

World Journal of Urology

Book Series Title

Edition

DOI

10.1007/s00345-023-04482-0

item.page.datauri

Link

Rights

Rights URL (CC Link)

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details